03/15/23 7:45 AMNasdaq : ROIV, ROIVW clinical trial Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old46.4% of subjects receiving VTAMA cream, 1% achieved the primary endpoint of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD TM) response of clear (0) or almost clear (1) with at least a 2-grade improvement from baseline at Week 8, versus 18.0% on vehicle (P<0.0001) AllRHEA-AIpositive
03/14/23 4:07 PMNasdaq : ROIV, ROIVW conferencesclinical trialRoivant to Host Investor Call at 8:00 AM ET on Wednesday, March 15 to Review Results from ADORING 2 Phase 3 Trial in Atopic DermatitisRoivant Sciences (Nasdaq: ROIV) today announced that it will host a live investor call and webcast at 8:00 AM ET on Wednesday, March 15 to review topline results from the ADORING 2 study, one of twoRHEA-AIneutral
03/14/23 8:00 AMNasdaq : ROIV, ROIVW conferencesclinical trialProteovant Therapeutics to Present Preclinical Data from Estrogen Receptor and IKZF2 Protein Degrader ProgramsProteovant Therapeutics, a Roivant Sciences (Nasdaq: ROIV) company leveraging the process of protein degradation to discover and develop transformative medicines for the treatment ofRHEA-AIneutral
03/07/23 8:00 AMNasdaq : ROIV, ROIVW managementCovant Therapeutics Announces the Formation of its Scientific Advisory Board to Support Platform and Pipeline AdvancementCovant Therapeutics, an innovative covalent drug discovery company incubated by Roivant Sciences (Nasdaq: ROIV), today announced the formation of its Scientific Advisory Board (SAB). Covant uses its unprecedented high-throughput chemoproteomics platformRHEA-AIneutral
02/21/23 8:32 PMNasdaq : ROIV, ROIVW managementRoivant Sciences Announces Change to its Board of DirectorsRoivant Sciences (Nasdaq: ROIV) today announced that its founder Vivek Ramaswamy has stepped down from the company’s board of directors to focus on his U.S. presidential campaign. Vivek founded Roivant inRHEA-AIvery positive
02/13/23 7:00 AMNasdaq : ROIV, ROIVW earningsRoivant Sciences Reports Financial Results for the Third Quarter Ended December 31, 2022 and Provides Business Update$9.2M in net product revenue from VTAMA reported for the quarter ended December 31, 2022, with nearly 100,000 VTAMA prescriptions written by approximately 8,600 unique prescribers since launch VTAMA payor coverage significantly expanded, with 57% of commercial lives now covered ADORING 1 and 2RHEA-AIneutral
02/02/23 9:14 PMNasdaq : ROIV, ROIVW offeringRoivant Sciences Announces Pricing of Upsized Public Offering of Common SharesRoivant Sciences (Nasdaq: ROIV) today announced the pricing of an upsized underwritten public offering of 26,666,666 of its common shares at a price to the public of $7.50 per share. All of the common sharesRHEA-AIneutral
02/01/23 4:05 PMNasdaq : ROIV, ROIVW offeringRoivant Sciences Announces Proposed Public Offering of Common SharesRoivant Sciences Ltd. (Nasdaq: ROIV) announced today that it has commenced an underwritten public offering of $150 million of common shares. In addition, Roivant expects to grant the underwriters a 30-dayRHEA-AIneutral
01/30/23 8:00 AMNasdaq : ROIV, ROIVW conferencesearningsRoivant to Report Financial Results for the Third Quarter Ended December 31, 2022 on Monday, February 13, 2023Quarterly investor call and webcast scheduled on Monday, February 13 at 8:00 a.m. ET Roivant will also participate in the SVB Securities Global Biopharma Conference in February and the Cowen 43rd Annual Health Care Conference in March BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Jan. 30,RHEA-AIneutral
01/04/23 6:05 AMNasdaq : ROIV, ROIVW clinical trialRoivant Announces Statistically Significant and Clinically Meaningful Results from the Induction Period of TUSCANY-2, a Large Global Phase 2b Study of Subcutaneous RVT-3101 for the Treatment of Ulcerative Colitis in Both the Overall and the Biomarker Positive Patient PopulationsRVT-3101 demonstrated statistically significant and clinically meaningful efficacy at each dose tested Across all patients treated with RVT-3101, the clinical remission and endoscopic improvement rates were 32% and 40%, respectively. Similar results were observed at the expected Phase 3 dose At theRHEA-AIpositive
